Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.
Neoadjuvant Chemotherapy|Sintilimab|Locally Advanced Gastric Cancer
DRUG: SOX+Sintilimab|DRUG: FLOT+Sintilimab
The rate of radical (R0) resection after neoadjuvant therapy, efficacy of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer., From the preoperative chemotherapy until the occurrence of adverse events, assessed up to 180 days
adverse event, adverse event caused by FLOT, SOX or Sintilimab treatment, which were coded using the Medical Dictionary Regulatory Activities version 20.1 and adverse event grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events, From the preoperative chemotherapy until the occurrence of adverse events, assessed up to 180 days|disease-free survival, from diagnosis to recurrence or death, From date of diagnosis until the first documented recurrence or death, assessed up to 60 months
This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.